Beijing Hanmi Pharmaceutical Co., Ltd.

2025 anticipates advancements in obesity treatments, space exploration, and quantum mechanics. Innovations include new GLP-1 based drugs, solar wind exploration satellites, lunar landers, and the operation of the first commercial fusion power plant. The year also marks the 100th anniversary of quantum mechanics and the 30th anniversary of the UN Climate Change Convention.

2024 saw healthcare industry turmoil over medical school quotas and martial law. Wegovy, a groundbreaking obesity drug, reshaped Korea's treatment landscape, despite concerns over misuse and adverse reactions. Its success spurred local and global pharmaceutical developments in obesity treatment.

Hanmi presented BH3120, a novel immunotherapy targeting PD-L1 and 4-1BB, at the SITC conference, highlighting its potential as a safer anticancer therapy. A Phase 1 trial in South Korea and the U.S. shows no dose-limiting toxicities, and a combination trial with KEYTRUDA is planned for early next year.

DelveInsight's report on Nonalcoholic Steatohepatitis (NASH) provides insights into historical and forecasted epidemiology, market trends, current treatment practices, emerging drugs, and market size from 2019 to 2032 in the United States, EU5, and Japan. Key companies and therapies in the NASH market are highlighted, including recent developments like Aligos Therapeutics' Phase 1 data presentation.